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IUFI is a pancreatic fi ceil-specific factor which binds to the sequence 5’-CPyCTAATG-3’ (CT box) within the human insulin gene enhancer. Here 
we show that IWFI is composed of 2 binding activities that can be separated by DEAE ion exchange chromatography. South Western blot analysis 
indicates that these distinct binding activities have apparent molecular weights of ii5 kDa and 46 kDa. 
Insulin gene; Transcription factor; Gene expression 
1. INTRODUCTION 
Regulation of.expression of the insulin gene involves 
discrete promoter and enhancer sequences located up- 
stream of the transcriptional start site [l]. A number of 
transcriptionally important DNA sequences have been 
identified in the rat I insulin gene [PI], the rat II insulin 
gene [Ml, and the human insulin gene [T-9]. These 
include both positively and negatively acting sequences 
[5,9-l l]. 
Mutational analysis has shown that the most impor- 
tant positively acting enhancer elements are two closely 
related sequences 5’-GCCATCTGC-3’ and Y-GCCA- 
TCTGG-3’ located at -108 and -233 in the rat insulin 
1 gene, respectively [121. Designated IEBI and II%2 (or 
Nir and Far), these sequences bind a factor of wide 
tissue distribution. which contains a helix loop helix 
motif [13-151. 
Located on the 3’ side of the IEBl and IEB2 sequen- 
ces are the CT1 and CTII boxes. These have the consen- 
sus sequence 5’-CPyCAATG, and both bind a p cell- 
soecific factor. IUFl 181. When linked to a heteroloaous 
Here we characterise further the insulin enhancer 
binding activity, IUFl, using a nuclear extract from a 
transplantable rat insulinoma [18]. The tumour is com- 
posed principally of p cells, and serves as a convenient 
source of gram-quantities of nuclear extract. 
2. EXPERIMENTAL 
2. I. Nuclear extracts 
Nuclear protein extracts were prepared from a transplantable rat 
insulinom:a, and from HYTM2.2.2 (an SV40 transformed hamster B 
ceil line), HeLa and BHK ceil lines as previously described [19]. 
2.2. DEAE ion exchange chromarogrphy 
DEAE ion exchange chromatography was performed on a Sphero- 
gel TSK DEAE-SPW column (7.5 mm x 4.5 cm) (Beckman I rtru- 
ments, High Wycombe. UK) equilibrated in 20 mM HEPES (pH 7.8), 
10% glycerol (v/v), 0.2 mM EDTA, 0.5 mM DTT, 1 mM PMSF 
(column buffer). Rat insulinoma nuclear protein extract (500 gi) was 
ioadcd on to the column, and bound protein was then &ted with a 
O-O.5 M NaCl gradient in column buffer over 40 min at a flow rate 
of 0.5 ml/min. Fractions were collected at 2 min intervals. Eiectropho- 
retie mobility shift assays (EMSAs) were performed as previously 
described [l91. 
p’romoter, a DNA f&bent containing the putativi rat 
I IUFl binding site has no enhancer activity by itself, 
but does appear to potentiate the activity of the HEB site 
in p cells [ 161. By screening a cDNA expression library 
from the insulin-secreting RIN cell line, Karlsson et al. 
[ 171 isolated a cDNA encoding a 38 kDa protein, M-1, 
which binds within the sequence TTAATAATCTAA- 
TTA. This sequence contains, in addition to the CT 
motif (TCTAAT), 3 copies of the motif TAAT, known 
to be important in the DNA-binding of homeodomain- 
containing proteins. 
Corvespo~rckwce ad&w K. Docherty, Department of Medicine, 
Queen Elizabeth Hospital, Birmingham, Bl5 2TH, UK 
2.3. South Western blotting 
Oligodeoxynucleotides (oiigos) were synthesised on a laboratory 
PCR Mate and purified using OPC cartridges. Double stranded oiigo 
concatemers were prepared by sequential 5’-phosphoryiation, using 
T4 poiynucleotide kinase, and ligation according to Vinson et al. [24]. 
500 ng oligo concatamers were subsequently labelled by nick transla- 
tion using [cr-“*P]dCTP to a specific activity of approx. 10s dpmlpg. 
The labelied oligo concatamers were centrifuged through a I ml Sep- 
hadex G-50 column equilibrated in IO mM Tris, I mM EDTA (pH 
7.4). 
.‘. Nuclear proteins (approx. 3Ogg) were subjected to SDS polyacryla- 
midc gel eiectrophoresis (SDS PAGE) (10% (w/v) acrylamide) and 
transferred onto a nitrocellulose filter (0.45 pm, Schieicher and 
Schueil. from Andetman and Co.. East Moleslev. Surrev) usine a 
semi-d& blotting system (39 mM glycine, 48 mM-iris, 0.057% §!X 
(w/v), 20% methanol (v/v), at 8 mAlcm2 filter for 1 S h. The nitrocel- 
lulosc filter was air dried for 30-60 min then subjected to a denatura- 
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Fig. 2. South Western blot analysis of nuclear extracts from rat insu- 
linoma (rin), WIT. I-?&a and BHK cells. Blots were probed with 
radiolabelled oligo Ii. 14C protein molecular weight markers are shown 
in track M. 
Fig. 1, Electropkoretic mobility shift assay of nuclear extracts from 
rat insulinoma (rin), WIT, I-IeEa and BHK cells. Each extract was 
assayed with radiolabelled oligo B, Bml and Bm2, Assays were also 
performed with radiolabelled oligo B, and excess unlabelled oligo Bml 
or Bm2 as competitor. 
tion (6 M guanidine hydrochloride)-renaturation cycle [24]. Binding 
sites on thefiltcr were blocked by incubation in binding buffer (25 mM 
HEPES (pH 7.9) 3 mM MgCIr. 50 mM KCI, 1 mM DTT) containing 
5% (w/v) non-fat dried milk powder at 4OC for 30 min, then rinsed 
briefly in binding buffer plus 0.25% (w/v) non-fat dried milk powder. 
The filter was incubated overnight at 4°C in binding buffer containing 
0.25% (w/v) non-fat dried milk powder, approx. IO* dpm/ml of 32P- 
labelled oligo concatamcrs and 8 gg/ml poly(dIqdC)*poly(dIdC). The 
Alter was washed in binding buffer plus 0.25% non-fat dried milk 
powder (3 x 5 min at 4OC), and dried and autoradiographed (Euji RX 
film). 
3. RESULTS 
oligo Bml in excess abolished all bands, while oligo 
Bm2 abolished band a, but had no effect on bands b and 
c. Taken together, these data suggested that the major 
bands b and c were related to binding at the CT site in 
oligo B. Methylation interference analysis confirmed 
that bands b and c represented protein binding at iden- 
tical sites (the CT motif) within oligo B (data not 
shown). The minor bands resulted from proteins bind- 
ing at other sites in oligo I% Retarded bands b and c 
were unaffected by salt (NaCl) concentrations over the 
range 50400 r&l, while the minor bands were abolish- 
ed at salt concentrations above approx. 100 mM (data 
not shown). Similar results were obtained with the HIT 
nuclear extract (Fig. 1, tracks 6-10) with minor differen- 
ces in the mobility of bands. These could result from 
species differences in similar binding proteins. 
IUFl binding activity was characterised using 3 dou- 
ble-stranded 30-mers corresponding to sequences in the 
human insulin gene: oligo I3 S-CCCCTGGT- 
TAAGACTCTAATGACCCGCTGG-3’, which con- 
tains a functional IUFl binding site (underlined); oligo 
Bml 5’-CCCCTGGTTAAGAC~CTAATGAKCCG- 
CTGG-3’, which contains a T/C transversion which 
does not affect HUFl binding; and oligo Bm2 S- 
CCCCTGGTTAAGAICTCTACTGA/CeCGCTGG- 
3’, which contains an A/C transversion which abolishes 
IUFl binding [8,9]. 
In the MeEa nuclear extract, oligo l3 generated 2 
major slow mobility bands, while oligo Bml generated 
3 major slow mobility bands, and oligo Bm2 four major 
slow mobility bands (Fig. 1, tracks 11-15). In BHK 
nuclear extract, oligos B, Bml and Bm2 generated a 
single slow mobility band, which ran as a doublet 
(tracks 16-20). These results confirmed that the IUFl 
binding activity was not present in HeLa or BHK cells, 
but that they contained proteins which bound to oligo 
B at uncharacterised sites. IUFl binding activity was 
also absent from nuclear extracts prepared from the 
mouse corticotrophic cell line AtT20 (data not shown). 
In the rat insulinoma extract, 3 major retarded bands The proteins binding to oligo B in the various cell 
(a, b and c) and several minor bands, including band d, extracts were further characterized by probing a South 
were observed using oligo B in an EMSA. In the same Western blot with oligo B. In the insulinoma and HIT 
extract oligo Bml generated band b, and bands a, c and cell extracts 3 major proteins of M, 115 kDa, 65 kDa, 
d, which were much fainter. Oligo Bm2 generated bands and 46 kDa were observed (Fig. 2). In the WeLa extract, 
a and d. In competition studies using oligo E3 as probe, a single protein of M, 115 kDa was observed together 
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115 kDa (Fig. 3B). The 115 and the 65 kDa protein 
eluted in fraction 10. The 46 kDa protein eluted in 
fractions 11 and 12; approx. 10% in fraction 11 and 90% 
in fraction 12. The 95 kDa protein eluted in fractions 
17 and 18, and the 100 kDa protein in fraction 18. 
c- 
The column fractions were also analysed using oligo 
Bm2. The two minor EMSA bands a and d (see Fig. 1) 
were localised to fractions 13114 and 10 respectively 
(data not shown). SW blot analysis with oligo Bm2 
revealed 2 proteins of il4, 65 kDa and 115 kDa in the 
rat insulinoma extract: the 46 kDa protein observed 
with probe B did not bind to oligo Bmf. The 65 kDa 
protein eluted in fraction 10, while the I1 5 kDa protein 
was separated into 2 components which eluted in frac- 
tions 12113 and 18 (Fig. 4). Thus, the 65 kDa protein in 
fraction 10 binds both oligos I3 and Bm2. It appears to 
be a protein of restricted tissue distribution, which binds 
non-specifically to DNA sequences, since it was also 
shown to bind to a variety of other short unrelated 
oligos (data not shown). 
4. DISCUSSION 
The pancreatic p cell-specific nuclear factor, IIJFI , 
binds to the sequence 5’-CPyCTAATG-3’ (CT box) at 
positions, -313, -217 and -84 in the human insulin 
gene [8]. The two proximal CT boxes are paired to IEB 
motifs with a short separating sequence, and it has been 
suggested that the close juxtaposition of the EBB and 
CT boxes may constitute a B cell-specific proto-enhan- 
cer [9]. The IEB box is the dominant positive-acting 
enhancer element while the CT box may serve to poten- 
tiate activity of this motif [16]. The function of the distal 
CT box is unknown, although it is located within a 
region of the gene which exhibits Dositive enhancer ac- 
ti<ty (Clark and Docherty, in preparation). 
This study reveals that the p cell-specific IUFl activ- 
ity is comprised of 2 components designated b and c. 
Competition studies in EMSA with oligos containing 
mutations in the IUFl binding site, along with methyla- 
tion interference analysis, confirmed that both compo- 
nents involved protein-DNA interactions at the CT 
motif. These components could be separated from each 
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Fig. 3. (A) Electrophoretic mobilit.y shift assay of rat insulinoma 
nuclear cxlrnct DEAE column fractions. Rat insulinoma extract was 
applied to the DEAE column and eluted with a O-O.5 M N&l gradient 
as described in section 2. Twenty fractions (1 ml) were collected, and 
10~11 of each fraction assayed using radiolabelled oligo B. Tracks are: 
rin, rat insulinoma nuclear extract; 2-20, DEAE column fraction 2-20. 
(B) South Western blot analysis of rat insulinoma nuclear extract 
DEAE column fractions. The twenty DEAE column fractions from 
above were precipitated with ice-cold trichloracetic acid and subjected 
to South Western blot analysis using radiolabelled oligo B.Track M, 
14C protein molecular weight markers. 
with at least 4 minor proteins of Mr 30-40 kDa, while 
the BI-IK extract contained a single prominent protein 
of M, 65 kDa (Fig. 2). 
Because the insulinoma extract was available in rela- 
tively large quantities, it was possible to further charac- 
terise these DNA binding proteins by DEAE ion ex- 
change chromatography. Twenty fractions were collec- 
ted from the DEAE ion exchange column, and each 
fraction analysed by EMSA using oligo I3 as probe (Fig. 
3A). The 3 major binding activities observed in the un- 
fractionated extract were separated on the column; acti- 
vities corresponding to band a in fractions 13 and 14, 
band b in fraction 11, and band c in fraction 10. South 
Western (SW) blot analysis of the rat insulinoma nu- 
clear extract revealed the major proteins of 46 kDa and 
65 kDa, and a cluster of 3 proteins of M, 95, 100 and 
I l . 
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Fig. 4. South Western blot analysis of rat insulinoma nuclear extract 
DEAE column fractions. The twenty DEAE column fractions (see 
legend to Fig. 3) were subject to South Western blot analysis using 
radiolabelled oligo Bm2. 
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other by E>EAE chromatography. The high mobility $0 
cell-specific EMSA component (band c) co-fractionated 
with two major proteins of 11.5 kDa and 65 kDa. Other 
oligos bound to the 65 kDa protein suggesting that it 
was unlikely to contribute to /3 cell-specific interactions 
with oligo B. The 115 kDa protein interacted with se- 
quences containing the CT box, i.e. it bound to oligo B 
but not to oligo Bm2, which suggests that this protein 
may be respornsible for the fi cell-specifis E&ISA com- 
plex c. Besides this protein there were several other 
proteins of M, 95-I IO kDa, which were not p cell-speei- 
fit. They did not bind to the CT box within oligo I3 (i.e. 
bound oligo B and Bm2), and eluted from the DEAE 
column in fractions 13/14 and 18. 
Assignment of the molecular size of the/j cell-specific 
EMSA con-rplex b by SW blotting was more difficult. 
Activity in the EMSA assay overlapped with that of a 
46 kDa proteixr, however the maximal activities did not 
coincide. Such a discrepancy could arise if the 46 kDa 
protein were associated with a negative factor yielding 
a complex of slightly more acidic nature. This possibi- 
lity and the possibility that the 46 kDa protein re- 
presents the mature form of the product of the Id-l 
cDNA [17] warrants further investigation, 
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